- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03944109
The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia
The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia - A PhaseⅠb/Ⅱ Randomized, Double-Blind, Placebo-Controlled Clinical Study
This is a randomized, double-blind, placebo- controlled phaseⅠb/Ⅱclinical study. Totally 108 subjects are planned to enrolled with 36 subjects in three low-dose groups (group 1, group 2 and group 3) and 72 subjects in three high-dose groups (group 4, group 5, and group 6).12 subjects with hyperlipidemia who received statin stable treatment for more than 28 days are enrolled in each low-dose group, randomly given SHR-1209 or placebo treatment at a ratio of 5:1. 24 subjects with hyperlipidemia who received statin stable treatment for more than 28 days are enrolled in each high-dose group, randomly given SHR-1209 or placebo treatment at a ratio of 5:1. The primary objective of this study is to evaluate the safety, tolerability, and efficacy of multiple subcutaneous injections of SHR-1209 in hyperlipidemia subjects treated with stabilized dose of statin. Groups detail as follows:
- SHR-1209 dose 1 /placebo frequence 1
- SHR-1209 dose 2 /placebo frequence 2
- SHR-1209 dose 3 /placebo frequence 3
- SHR-1209 dose 4 /placebo frequence 1
- SHR-1209 dose 5 /placebo frequence 2
- SHR-1209 dose 6 /placebo frequence 3
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Sun Yat-Sen Memorial Hospital ,The Second Affiliated Hospital of Sun Yat-Sen University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 and ≤65 years old;
- Subjects who are receiving statin therapy at the time of screening or who are eligible for statin therapy can randomized to receive a stable dose of statin therapy for more than 28 days and are willing to maintain stable statin therapy in this study;
- Low-density lipoprotein cholesterol (LDL-C) level ≥2.6mmol/L of subjects who receiving statin and/or other lipid-lowering therapy at the time of screening, or LDL-C≥ 3.4mmol/L of subjects who didn't receive any-lowering therapy at the time of screening, and LDL-C still ≥2.6mmol/L before randomization;
- Fasting triglycerides ≤4.5 mmol/L;
- Body mass index (BMI) ≥18 and ≤ 35 kg/m2;
- Signed informed consent.
Exclusion Criteria:
- A clinical history of drug allergy or a history of atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known allergy to experimental or similar experimental drugs;
- Diagnosis of homozygous familial hypercholesterolemia;
- New York heart association (NYHA) defined Ⅱ - Ⅳ history of heart failure;
- History of acute coronary syndrome (e.g. myocardial infarction, hospitalization for unstable angina), or percutaneous coronary intervention, or coronary artery bypass graft, or history of cerebrovascular disease, within 12 months prior to screening;
- Uncontrolled severe arrhythmias that are not controlled by drugs or other therapy within 12 months prior to enrollment;
- Uncontrolled hypertension (systolic blood pressure ≥ 160 and/or diastolic blood pressure ≥ 100 mmHg);
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma pancreatic acyl transferase (GGT), more than 2.5x ULN;
- Subjects with previous malignant tumor diseases. etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR-1209
Participants received one of 6 dose levels of SHR-1209 administered as multiple subcutaneous doses.
|
Pharmaceutical form: lyophilized formulation Route of administration: subcutaneous |
Placebo Comparator: Placebo
Participants received matching placebo dose regimens by subcutaneous injection.
|
Pharmaceutical form: lyophilized formulation Route of administration: subcutaneous |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary efficacy end point:Percent change from baseline to end of the dosing interval in LDL-C.
Time Frame: Baseline to day 113 for group1,2,4,5 or day 169 for group 3,6
|
Baseline to day 113 for group1,2,4,5 or day 169 for group 3,6
|
Primary safety end point:Number of subjects with adverse events.
Time Frame: Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5
|
Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absolute change from baseline to end of the dosing interval in LDL-C.
Time Frame: Baseline to day 113 for group1,2,4,5 or day 169 for group 3,6
|
Baseline to day 113 for group1,2,4,5 or day 169 for group 3,6
|
Percent change from baseline to day 85 in LDL-C.
Time Frame: Baseline to day 85 for all 6 groups
|
Baseline to day 85 for all 6 groups
|
Absolute change from baseline to day 85 in LDL-C.
Time Frame: Baseline to day 85 for all 6 groups
|
Baseline to day 85 for all 6 groups
|
Percent change in PCSK9.
Time Frame: Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5
|
Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5
|
Absolute change in PCSK9.
Time Frame: Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5
|
Baseline to day 169 for group 1,3,4,6 or day 141 for group 2,5
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR-1209-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipidemia
-
Drug Commission of the German Medical AssociationMadaus AGTerminatedHypercholesterolemia | Combined Hyperlipidemia
-
Misr University for Science and TechnologyActive, not recruiting
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesterolemia and HyperlipidemiaChina
-
Jeil Pharmaceutical Co., Ltd.CompletedHypertension With HyperlipidemiaKorea, Republic of
-
PfizerWithdrawnPrimary Hyperlipidemia or Mixed DyslipidemiaChina
-
ShionogiIntegriumCompletedCombined HyperlipidemiaUnited States
-
IlDong Pharmaceutical Co LtdCompletedHypertension With HyperlipidemiaKorea, Republic of
-
HK inno.N CorporationCompletedHypertension With Hyperlipidemia
-
LG Life SciencesCompletedHypertension, HyperlipidemiaKorea, Republic of
Clinical Trials on SHR-1209
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed HyperlipemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPrimary HypercholesterolemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesterolemia and HyperlipidemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesteremiaChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownFamilial Hypercholesterolemia
-
Jiangsu HengRui Medicine Co., Ltd.CompletedMixed Hyperlipidemia | Non-familial HypercholesterolemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedAdvanced MalignanciesAustralia, China
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Non-small Cell Lung CancerChina